HUMATIN (paromomycin sulfate) · PARKEDALE
HUMATIN is FDA-approved to treat 2 conditions (same as PAROMOMYCIN SULFATE).
Details
- Status
- Discontinued
- First Approved
- 1969-03-24
- Routes
- ORAL
- Dosage Forms
- CAPSULE, SYRUP
HUMATIN Approval History
What HUMATIN Treats
2 indicationsHUMATIN is approved for 2 conditions since its original approval in 1969. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Amebiasis
- Hepatic Coma
Same approved indications as PAROMOMYCIN SULFATE (same active ingredient).
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03096457 | ABF-BO-2016-102 | Ph 2, Ph 3 | completed | Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
HUMATIN FDA Label Details
Indications & Usage
HUMATIN is FDA-approved to treat 2 conditions — same approved indications as PAROMOMYCIN SULFATE.
Track HUMATIN with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.